Physiologically Based Pharmacokinetic Modeling of Fruquintinib and Its Metabolite to Assess Drug–Drug Interaction Liability as an Object or Precipitant
CPT: Pharmacometrics & Systems Pharmacology · 2026-11 · 15 (11)
DOI: 10.1002/psp4.70356 ↗Kurz gefasst
Fachartikel in der Zeitschrift CPT: Pharmacometrics & Systems Pharmacology, online erschienen am 11.11.2026. Verfasst von Ian E Templeton und 4 weiteren Autor:innen. Beteiligte Einrichtung: Certara UK Limited, Simcyp Division, Sheffield, UK. Hauptthemen laut MEDLINE: Benzofurans, Quinazolines, Models, Biological. Die Arbeit nennt 18 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY-NC 4.0). Gefördert von: HUTCHMED International Corporation & Takeda Pharmaceuticals U.S.A. Inc..
Abstract (Originalsprache)
Fruquintinib is approved, including in the United States and Europe, for previously treated metastatic colorectal cancer, regardless of biomarker status. Using in vitro and clinical data, physiologically based pharmacokinetic (PBPK) models were developed for fruquintinib and M11, a major metabolite of fruquintinib. The models were applied to evaluate the potential impact of strong/moderate/weak cytochrome P450 (CYP) and 3A4 (CYP3A4) inhibitors and inducers on the pharmacokinetics of fruquintinib and M11. In addition, the PBPK models were applied to evaluate the potential for P‐glycoprotein or breast cancer resistance protein (BCRP)‐mediated drug–drug interactions, with fruquintinib and M11 as precipitants (inhibitors). The simulations indicated that the changes in plasma exposure of fruquintinib area under the curve (AUC) geometric mean ratio (GMR) during administration with strong/moderate/weak inhibitors of CYP3A4 are negligible (< 1.25), and M11 interactions are weak with strong inhibition. Simulated changes in plasma exposure of fruquintinib in the presence of rifampin (a strong CYP3A4 and moderate CYP2C9 inducer) were > 0.20, but ≤ 0.50 (no significant change in M11). Fruquintinib AUC GMRs were > 0.50, but ≤ 0.80 with moderate CYP3A4 inducers, while the ratio fell between > 0.80 and 1.00 in the presence of weak CYP3A4 inducers. The effects of fruquintinib on the pharmacokinetics of P‐glycoprotein or BCRP substrates were not clinically significant. These analyses support avoiding concomitant use of strong, and if possible, moderate CYP3A4 inducers with fruquintinib. In addition, no dose adjustments for fruquintinib are required in the presence of CYP3A4 inhibitors, or for medications that are substrates of P‐glycoprotein or BCRP when used concomitantly with fruquintinib.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- Certara UK Limited, Simcyp Division, Sheffield, UK.
- HUTCHMED, Florham Park, New Jersey, USA.
- Takeda Development Center Americas, Inc. (TDCA), Cambridge, Massachusetts, USA.
ORCID-Profile: Ian E Templeton, Caly Chien, Neeraj Gupta, Xiaofei Zhou
Förderung
- HUTCHMED International Corporation & Takeda Pharmaceuticals U.S.A. Inc.
Zitieren
APA
Templeton, I. E., Jones, H. M., Chien, C., Gupta, N., & Zhou, X. (2026). Physiologically Based Pharmacokinetic Modeling of Fruquintinib and Its Metabolite to Assess Drug–Drug Interaction Liability as an Object or Precipitant. CPT: Pharmacometrics & Systems Pharmacology, 15(11). https://doi.org/10.1002/psp4.70356
Vancouver
Templeton IE, Jones HM, Chien C, Gupta N, Zhou X. Physiologically Based Pharmacokinetic Modeling of Fruquintinib and Its Metabolite to Assess Drug–Drug Interaction Liability as an Object or Precipitant. CPT: Pharmacometrics & Systems Pharmacology. 2026;15(11). doi:10.1002/psp4.70356
BibTeX
@article{Templeton2026,
author = {Templeton, Ian E and Jones, Hannah M and Chien, Caly and Gupta, Neeraj and Zhou, Xiaofei},
title = {Physiologically Based Pharmacokinetic Modeling of Fruquintinib and Its Metabolite to Assess Drug–Drug Interaction Liability as an Object or Precipitant},
journal = {CPT: Pharmacometrics & Systems Pharmacology},
year = {2026},
volume = {15},
number = {11},
doi = {10.1002/psp4.70356}
}
EUVIMED